Halozyme Therapeutics Inc. (HALO)
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)
Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the best option for those looking for undervalued stocks?
Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Halozyme says €2 billion takeover of Evotech would create leader in drug discovery
Halozyme says the combined company would have an estimated $2 billion in revenue in 2025.
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
On Thursday, Halozyme Therapeutics, Inc. HALO submitted a non-binding proposal to Evotec SE EVO to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value of 2.0 billion euros (around $2.11 billion).
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Halozyme: Looking For More Growth Following Record Q3 Earnings
Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong partnerships with J&J and Roche. The partnership model using ENHANZE tech mitigates risks, enhances operational efficiency, and offers partners a way to avoid patent cliffs, ensuring long-term growth. Despite strong near-term growth prospects, potential patent disputes and reliance on partnerships pose risks; vigilance is necessary to maintain Halozyme's growth stock status.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme Announces Record Earnings, Guidance
Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.
HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up
Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024.
Halozyme Therapeutics, Inc. (HALO) Q3 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Helen Torley - President, Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Tram Bui - Vice President of Investor Relations, Corporate Communications Conference Call Participants Brendan Smith - TD Cowan Mike DiFiore - Evercore ISI Jason Butler - Citizens JMP Corinne Jenkins - Goldman Sachs Mitchell Kapoor - H.C. Wainwright Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Operator Good afternoon.
